Globeimmune Inc
OTC:GBIM

Watchlist Manager
Globeimmune Inc Logo
Globeimmune Inc
OTC:GBIM
Watchlist
Price: 0.0001 USD Market Closed
Market Cap: 575 USD

Net Margin
Globeimmune Inc

-33.3%
Current
-127%
Average
-6.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-33.3%
=
Net Income
-2.1m
/
Revenue
6.2m

Net Margin Across Competitors

No Stocks Found

Globeimmune Inc
Glance View

Market Cap
575.2 USD
Industry
Biotechnology

GlobeImmune, Inc. is a biopharmaceutical company. The company is headquartered in Louisville, Colorado. The company went IPO on 2014-07-02. The firm is engaged in development of products for the treatment of cancer and infectious diseases. The firm provides Tarmogen platform, which activate the immune system by stimulating a subset of white blood cells called T cells that destroy infected or malignant cells, in contrast to traditional vaccines which predominately stimulate antibody production. Tarmogens also reduce the number and function of regulatory T cells, thus further enabling the antigen-specific cellular immune response. The firm's oncology product candidates include GI-6301, GI-6207 and GI-4000. The firm's infectious disease product candidates include GS-4774, GI-19000, GI-2010 and GI-18000.

GBIM Intrinsic Value
Not Available
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-33.3%
=
Net Income
-2.1m
/
Revenue
6.2m
What is the Net Margin of Globeimmune Inc?

Based on Globeimmune Inc's most recent financial statements, the company has Net Margin of -33.3%.

Back to Top